Portugal Pharmaceuticals and Healthcare Report Q1 2016

91 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: Fiscal loosening by the newly-initiated Socialist-led government in Portugal and rising private
consumption will benefit pharmaceutical sales in 2016. According to the latest data on market activity we
have revised upwards our pharmaceutical market forecast, although operating challenges will remain due
to high levels of debt in the public hospital sector. Meanwhile, with competitiveness to diminish due to the
partial reversal of austerity measures, we do not see major room for Portuguese industrial sectors to
become more attractive to investors in the near term, including the pharmaceutical sector. That said, longterm
demand for healthcare due to an ageing population will keep translating into the need for access to
medical treatment, supporting market growth over the forecast period.
Headline Expenditure Projections
? Pharmaceuticals: EUR3.43bn (USD4.59bn) in 2014 to EUR3.44bn (USD3.78bn) in 2015; 0.3% in local
currency and -17.7% in US dollar terms. Forecast revised upwards from last quarter in local currency
terms and US dollar terms.
? Healthcare: EUR16.07bn (USD21.53bn) in 2014 to EUR15.82bn (USD17.41bn) in 2015; 0.3% in local
currency and -17.7% in US dollar terms. Forecast revised downwards from last quarter in local currency
terms and US dollar terms.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Portugal 2013-2019) 7
SWOT 10
Industry Forecast 12
Pharmaceutical Market Forecast 12
Table: Pharmaceutical Sales, Historical Data And Forecasts (Portugal 2011-2019) 14
Healthcare Market Forecast 15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Portugal 2011-2019) 18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts 18
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts 19
Prescription Drug Market Forecast 19
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Portugal 2011-2019) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Portugal 2011-2019) 24
Generic Drug Market Forecast 25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Portugal 2011-2019) 27
Table: Top Generic Drugs By Value In 2011 27
Table: Average Price Of Top Generic Drugs By Value 2010-2011 28
OTC Medicine Market Forecast 29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Portugal 2011-2019) 31
Table: OTC Sales Outside Of Pharmacies By Therapeutic Group (Jan-Sep 2012) 32
Table: OTC Sales Outside Of Pharmacies By District (Jan-Sep 2012) 32
Table: OTC Sales Outside Of Pharmacies By Sales Outlet (Jan-Sep 2012) 33
Table: Portugal OTC Sales Outside Of Pharmacies By Active Ingredient (Jan-Sep 2012) 33
Pharmaceutical Trade Forecast 34
Table: Pharmaceutical Trade Data And Forecasts (Portugal 2013-2019) 37
Table: Pharmaceutical Trade Data And Forecasts local currency (Portugal 2013-2019) 37
Industry Risk/Reward Index 38
Western Europe Risk/Reward Index 38
Portugal Risk/Reward Index 44
Rewards 44
Risks 45
Regulatory Review 46
Regulatory Regime 46
Intellectual Property Issues 48
Pricing Regime 49
Reimbursement Regime 51
Pharmacoeconomics 52
Market Overview 54
Healthcare Sector 55
Table: Healthcare Resources (Portugal 2009-2014) 55
Table: Healthcare Personnel (Portugal 2009-2014) 55
Table: Healthcare Activity (Portugal 2009-2014) 56
Clinical Trials 56
Epidemiology 57
Competitive Landscape 59
Research-Based Industry 59
Generic Drugmakers 59
Table: Table: Multinational Market Activity 60
Pharmaceutical Distribution 60
Pharmaceutical Retail Sector 61
Table: Number Of Pharmaceutical Companies, Wholesalers, Pharmacies, Pharmacy Extensions And Drug Stores In Portugal 64
Company Profile 65
Hovione 65
Bial 69
Medinfar 73
Bluepharma 76
Demographic Forecast 80
Table: Population Headline Indicators (Portugal 1990-2025) 81
Table: Key Population Ratios (Portugal 1990-2025) 81
Table: Urban/Rural Population & Life Expectancy (Portugal 1990-2025) 82
Table: Population By Age Group (Portugal 1990-2025) 82
Table: Population By Age Group % (Portugal 1990-2025) 83
Glossary 85
Methodology 87
Pharmaceutical Expenditure Forecast Model 87
Healthcare Expenditure Forecast Model 87
Notes On Methodology 88
Risk/Reward Index Methodology 89
Index Overview 90
Table: Pharmaceutical Risk/Reward Index Indicators 90
Indicator Weightings 91

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Portugal 2013-2019)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Portugal 2011-2019)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Portugal 2011-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Portugal 2011-2019)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Portugal 2011-2019)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Portugal 2011-2019)
Table: Top Generic Drugs By Value In 2011
Table: Average Price Of Top Generic Drugs By Value 2010-2011
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Portugal 2011-2019)
Table: OTC Sales Outside Of Pharmacies By Therapeutic Group (Jan-Sep 2012)
Table: OTC Sales Outside Of Pharmacies By District (Jan-Sep 2012)
Table: OTC Sales Outside Of Pharmacies By Sales Outlet (Jan-Sep 2012)
Table: Portugal OTC Sales Outside Of Pharmacies By Active Ingredient (Jan-Sep 2012)
Table: Pharmaceutical Trade Data And Forecasts (Portugal 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts local currency (Portugal 2013-2019)
Table: Healthcare Resources (Portugal 2009-2014)
Table: Healthcare Personnel (Portugal 2009-2014)
Table: Healthcare Activity (Portugal 2009-2014)
Table: Table: Multinational Market Activity
Table: Number Of Pharmaceutical Companies, Wholesalers, Pharmacies, Pharmacy Extensions And Drug Stores In Portugal
Table: Population Headline Indicators (Portugal 1990-2025)
Table: Key Population Ratios (Portugal 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Portugal 1990-2025)
Table: Population By Age Group (Portugal 1990-2025)
Table: Population By Age Group % (Portugal 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Portugal Pharmaceuticals and Healthcare Report Q3 2014
    BMI View: Faster-than-expected economic growth last quarter has led us to revise our healthcare and pharmaceutical forecasts slightly upwards. As forecast previously, BMI expects Portugal's healthcare market to return to growth in 2015, while pharmaceuticals will not return to growth until 2019. This is because while Portugal exited its bailout programme in May 2014 without the need for a new financial package, government austerity measures are likely to curb pharmaceutical reimbursement. Portug...
  • Portugal Pharmaceuticals and Healthcare Report Q3 2015
    BMI View: Despite the registered recovery in Portugal's economic indicators in recent quarters, substantial risks will remain to pharmaceutical firms that sell drugs in the country, especially due to delays in payments by public hospitals and high levels of public and private debt. The registered improvements in domestic demand, pharmaceutical exports and manufacturing indices will be partially counterbalanced by the slow progress in structural reforms to enhance competitiveness, offering a mixe...
  • Portugal Pharmaceuticals and Healthcare Report Q4 2015
    BMI View: Despite sustained economic growth and buoyant consumption indicators, high public and private debt levels in Portugal will remain a significant drag on the country's attractiveness to pharmaceutical companies. While hospital debt levels and payment delays have declined in 2015, the ongoing inability of public hospitals to manage their finances is still a cause for concern. Meanwhile, although we forecast the next government administration to take office after October 2015 to embark on ...
  • Colombia Pharmaceuticals and Healthcare Report Q1 2016
    BMI View: A growing burden of chronic diseases, along with the Colombian government's push toward improving health coverage, will ensure the country's retained appeal to multinational drugmakers and healthcare suppliers. However, high levels of debt among some health insurance providers will fuel instability in the health care sector. Headline Expenditure Projections ? Pharmaceuticals: COP8,643bn (USD4.32bn) in 2014 to COP9,101bn (USD3.32bn) in 2015; +5.3% in local currency terms. Forecast broad...
  • Australia Pharmaceuticals and Healthcare Report Q3 2015
    BMI View: The domestic backlash against the Australian government's budget saving efforts focusing on areas of the healthcare sector, including general practice copayments, will translate into additional incentives for the government to place pressure on pharmaceutical expenditure. Patented drugs will continue to account for the majority of the pharmaceuticals market share in Australia, with this share to only slightly moderate over the next years. In fact, cost containment efforts will continue...